68Gallium-FAPI PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

390 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-13

Study Completion Date

2027-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This single-center pilot study is designed to explore the preliminary utility of the \[68Ga\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \[68Ga\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterizing IgG4-RD With 68Ga-FAPI PET/CT

NCT04125511

IgG4-related Disease

UNKNOWN EARLY_PHASE1

From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19

NCT06911476

PASC Post Acute Sequelae of COVID 19 Long COVID Long Covid-19 +6 more

NOT_YET_RECRUITING

68Ga-FAPI PET/CT to Detect Ongoing Fibroblast Activity in Post-acute COVID-19

NCT05981885

Post-Acute COVID-19 Post-Acute COVID-19 Infection Post-Acute COVID-19 Syndrome +1 more

COMPLETED

FAPI PET for Lung Fibrosis

NCT05365802

Interstitial Lung Disease Idiopathic Interstitial Pneumonias Drug-Induced Pneumonitis +4 more

RECRUITING EARLY_PHASE1

Characterizing Histiocytosis With 68Ga-FAPI PET/CT

NCT05803629

Histiocytosis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

\[68Ga\] Ga-FAPI is an innovative radiotracer in positron emission tomography (PET) coupled to scanner (CT: computed tomography). It targets the membrane glycoprotein FAP (Fibroblast Activation Protein), a specific surface marker of activated fibroblasts, these constituting one of the main populations of the tumor microenvironment. This radiotracer is the subject of a major development program in the field of oncology and hematologic malignancies. In many cancers, preliminary data suggest, in terms of diagnostic performance, the superiority of \[68Ga\] Ga-FAPI over the reference evaluation modality carried out with \[18F\] F-FDG. These results make it possible to consider, in the medium term, the integration of this imaging modality into routine care, for the initial evaluation and monitoring of certain tumor pathologies.

If oncology and hematology constitute the most obvious areas of application of \[68Ga\] Ga-FAPI, other areas of potential use were quickly mentioned, due to the involvement of activated fibroblasts in the processes. remodeling of the extracellular matrix and tissue repair in general, beyond tumor pathologies. Non-exhaustively, the potential interest of the radiotracer is thus suggested in the characterization of benign tumor pathologies, in the evaluation of ischemic tissues, in chronic inflammatory diseases and in fibrosing diseases. Numerous preliminary data show that it is relevant to develop knowledge concerning the contribution of \[68Ga\] Ga-FAPI to the evaluation of numerous benign pathologies.

It is in this general context that this single-center pilot study project falls, the general objective of which is to determine the preliminary interest of this imaging modality in different chronic inflammatory and/or fibrosing diseases. The pathologies included in this project were selected by taking into account the concomitant presence of unmet medical needs in terms of disease assessment and recognized local clinical research expertise in the area concerned. On these bases, 13 distinct clinical situations were selected, intended to enable the production of pilot data. This approach will be able to determine the interest in continuing clinical development in each area and will help to specify the modalities.

The 13 clinical situations selected for this pilot study are:

* Rheumatoid arthritis
* Spondyloarthritis
* Inflammatory enterocolopathies
* Liver fibrosis
* Fibrosing interstitial lung disease
* Systemic sarcoidosis
* Polymyalgia rheumatica and giant cell arteritis
* Primary Sjögren's syndrome
* Systemic scleroderma
* Systemic lupus
* Inflammatory myopathies
* Primary or secondary myelofibrosis
* Other orphan systemic diseases

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a single-center, descriptive and analytical pilot study, which will be implemented in 13 distinct and independent populations of patients with chronic inflammatory and/or fibrosing disease.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ga68-FAPI46 TEP scan

In addition to the usual routine care, the study adds the performance of a \[68Ga\] Ga-FAPI PET/CT scan

Group Type EXPERIMENTAL

68Ga-FAPI46

Intervention Type DIAGNOSTIC_TEST

Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

68Ga-FAPI46

Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged 18 or over.
* Affected by one of the pathologies concerned by the study (see Table 4)
* Satisfying the consensus classification criteria for the pathology (Table 3).
* Satisfying the corresponding clinical situation (Table 3).
* Negative urine pregnancy test for women of childbearing age.
* Affiliated with or benefiting from social security.
* Informed consent (personally dated and) signed by the participant or any representatives (impartial witness/trusted person).

Exclusion Criteria

* Patients unable to consent.
* Incapacitated adults.
* Pregnant or breastfeeding women.
* Patients refusing to participate in research.
* Known active cancer.
* Women of childbearing potential unwilling to use appropriate contraception (definitions given in Annex 1).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No